NASDAQ:RCMR1 RCM Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding R1 RCM Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.00 -0.06 (-0.74 %) (As of 04/6/2020 11:32 AM ET) Add Compare Share Today's Range$7.77Now: $8.00▼$8.2650-Day Range$7.57MA: $11.12▼$13.9152-Week Range$7.12Now: $8.00▼$13.99Volume68,191 shsAverage Volume1.63 million shsMarket Capitalization$915.68 millionP/E RatioN/ADividend YieldN/ABeta0.46 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves healthcare providers, including health systems and hospitals, physicians groups, and municipal and private emergency medical service providers, as well as intermountain homecare, hospice and palliative care, and durable medical equipment and infusion therapy business. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingR1 RCM has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.25, R1 RCM has a potential upside of 90.6% from its current price of $8.00.Amount of Analyst CoverageR1 RCM has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesR1 RCM has received 209 “outperform” votes. (Add your “outperform” vote.)Underperform VotesR1 RCM has received 306 “underperform” votes. (Add your “underperform” vote.)Community SentimentR1 RCM has received 59.42% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote “Outperform” if you believe RCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldR1 RCM does not currently pay a dividend.Dividend GrowthR1 RCM does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, R1 RCM insiders have bought more of their company's stock than they have sold. Specifically, they have bought $144,804.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders60.50% of the stock of R1 RCM is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.69% of the stock of R1 RCM is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for R1 RCM are expected to grow by 78.95% in the coming year, from $0.38 to $0.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of R1 RCM is -72.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of R1 RCM is -72.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioR1 RCM has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioR1 RCM has a P/B Ratio of 50.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Management services Sub-IndustryHealth Care Services SectorFinance Current SymbolNASDAQ:RCM Previous SymbolNYSE:RCM CUSIP00438V10 CIK1472595 Webhttp://www.r1rcm.com/ Phone312-324-7820Debt Debt-to-Equity Ratio19.69 Current Ratio0.93 Quick Ratio0.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio21.05 P/E Growth1.92 Sales & Book Value Annual Sales$1.19 billion Price / Sales0.77 Cash Flow$0.61 per share Price / Cash Flow13.13 Book Value$0.16 per share Price / Book50.00Profitability EPS (Most Recent Fiscal Year)($0.08) Net Income$12 million Net Margins1.01% Return on Equity116.79% Return on Assets1.31%Miscellaneous Employees22,500 Outstanding Shares114,460,000Market Cap$915.68 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive RCM News and Ratings via Email Sign-up to receive the latest news and ratings for RCM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RCM Rates by TradingView R1 RCM (NASDAQ:RCM) Frequently Asked Questions How has R1 RCM's stock been impacted by COVID-19 (Coronavirus)? R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RCM shares have decreased by 21.3% and is now trading at $8.00. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of R1 RCM? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for R1 RCM. When is R1 RCM's next earnings date? R1 RCM is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for R1 RCM. How were R1 RCM's earnings last quarter? R1 RCM Inc (NASDAQ:RCM) released its earnings results on Thursday, February, 20th. The healthcare provider reported $0.01 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.04 by $0.03. The healthcare provider earned $314 million during the quarter, compared to analysts' expectations of $318.36 million. R1 RCM had a return on equity of 116.79% and a net margin of 1.01%. R1 RCM's quarterly revenue was up 19.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.10) EPS. View R1 RCM's earnings history. What guidance has R1 RCM issued on next quarter's earnings? R1 RCM issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.3-1.4 billion, compared to the consensus revenue estimate of $1.36 billion. What price target have analysts set for RCM? 4 brokerages have issued twelve-month price objectives for R1 RCM's stock. Their forecasts range from $14.00 to $17.00. On average, they expect R1 RCM's share price to reach $15.25 in the next year. This suggests a possible upside of 90.6% from the stock's current price. View analysts' price targets for R1 RCM. Has R1 RCM been receiving favorable news coverage? News articles about RCM stock have been trending very negative on Monday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. R1 RCM earned a news impact score of -3.3 on InfoTrie's scale. They also gave media stories about the healthcare provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutR1 RCM. Are investors shorting R1 RCM? R1 RCM saw a increase in short interest in March. As of March 13th, there was short interest totaling 7,444,000 shares, an increase of 10.1% from the February 27th total of 6,760,000 shares. Based on an average daily volume of 999,400 shares, the short-interest ratio is presently 7.4 days. Currently, 7.5% of the company's shares are short sold. View R1 RCM's Current Options Chain. Who are some of R1 RCM's key competitors? Some companies that are related to R1 RCM include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), CorVel (CRVL), MEDNAX (MD), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). What other stocks do shareholders of R1 RCM own? Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include Alibaba Group (BABA), NVIDIA (NVDA), Baozun (BZUN), Marvell Technology Group (MRVL), JD.Com (JD), Model N (MODN), Baidu (BIDU), Perficient (PRFT), BioDelivery Sciences International (BDSI) and NMI (NMIH). Who are R1 RCM's key executives? R1 RCM's management team includes the following people: Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 48)Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 49)Mr. Richard B. Evans Jr., Sr. VP, Interim CFO, Corp. Controller & Chief Accounting Officer (Age 51)Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.Mr. Corey Perman, Exec. VP of Compliance & Risk What is R1 RCM's stock symbol? R1 RCM trades on the NASDAQ under the ticker symbol "RCM." How do I buy shares of R1 RCM? Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is R1 RCM's stock price today? One share of RCM stock can currently be purchased for approximately $8.00. How big of a company is R1 RCM? R1 RCM has a market capitalization of $915.68 million and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe. View additional information about R1 RCM. What is R1 RCM's official website? The official website for R1 RCM is http://www.r1rcm.com/. How can I contact R1 RCM? R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: Conference Calls and Individual Investors
